Rx-360 Summary of EUs Falsified Medicines Directive rule (Article 46b 2011/62/EU)
On 2 July 2013, the EU’s Falsified Medicines Directive rule (article 46b 2011/62/EU) requiring “written confirmations” to accompany each consignment of API imported into the EU for use in commercial Human Health drug product went into effect.
The Heads of Medicines Agencies (HMA) of the EU Member States have published a guideline to ensure a consistent approach is used for the release of APIs under this rule. The guideline provides a process map to follow in the case that an imported API consignment, which is not from countries listed under article 111b of te Directive, is not accompanied by a “written confirmation”.
The process asks for risk assessments to be provided to EMA (European Medicines Agency) and the European Commission by the national competent authority when no “written confirmation” is present and no waiver exists. This process is expected to be necessary only for a short interim period while these new rules are being implemented across the EU. The intention is to enable the EMA to monitor the situation, to coordinate inspections as needed and to keep the network informed.
To view or download the document, click here
Related News
-
News New WHO health emergency guidelines expect full transparency from Big Pharma
The WHO are proposing a new set of pandemic guidelines to set out how future global health crises should be handled. -
News Biden's $2 billion Biotech Boost
President Biden issues executive order to bolster U.S. biomanufacturing sector. -
News US FDA grants priority review for Eisai and Biogen's Alzheimer's drug
Decision by US drug regulator on lecanemab expected by early next year -
News Panaxia's medical cannabis facility in Malta gains EU-GMP standard
This second facility gives the company a significant power multiplier for export capacity and geographical reach -
News CPHI Discover: Remote excipient audits are on the increase, but we must do more to develop novel excipients
Ahead of the session, Value Added Excipients to Unlock the Potential of APIs, at CPHI Discover on Thursday 18th May – global pharma’s largest ever virtual gathering – we spoke with one of the speakers, Dr Iain Moor... -
News Pharma Explained: What is Quality Risk Management & cGMPs?
Need clarity on determining your QA from your QbD and your cGMPs? You’re not alone! In our new Pharma Explained series from CPHI, we bring you clear cut definitions from industry experts on a myriad of Pharma Terms, delivered in bitesize video presenta... -
News Former FDA Commissioner lays out roadmap for building out excess capacity to deal with pandemic situations
Dr Scott Gottlieb shares insights into COVID-19 vaccine development, the upcoming US election and pharma pricing at the CPHI Festival of Pharma -
News Successful MHRA regulatory inspection for Scottish CMO Symbiosis
Inspection conducted remotely using video-conferencing and an online private document sharing platform.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance